COSCIENS Biopharma Inc. (TSX:CSCI)

Canada · Delayed Price · Currency is CAD

8.75

0.00 (0.00%)

Oct 1, 2026, 2:13 PM EST

COSCIENS Biopharma Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	8.73	7.5	9.59	7.14	14.57	5.26
Revenue Growth	-3.02%	-21.79%	34.22%	-50.98%	177.03%	44.03%
Gross Profit	3.98	2.57	4.73	2.94	8.56	5.17
Operating Income	-6.21	-10.44	-9.94	-4.63	4.32	-8.67
Net Income	6.55	-10.36	-15.31	-3.49	3.45	-8.37
Earnings Per Share	6.22	-9.82	-17.79	-5.67	5.58	-21.84
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Active Ingredient	8.26	7.04	8.49	7.14	14.57	-
Biopharmaceutical	-	0.46	1.1	-	-	5.26
Total	8.73	7.5	9.59	7.14	14.57	5.26

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	5.28	7.31	16.39	6.68	50.61	65.3
Total Debt	1.96	2.15	2.31	1.7	0.18	0.16
Net Cash (Debt)	3.32	5.16	14.08	4.98	50.43	65.14
Net Cash Growth	-53.05%	-63.37%	182.79%	-90.13%	-22.58%	170.43%
Net Cash Per Share	3.15	4.89	16.37	8.09	81.58	170.04

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-3.72	-8.47	-14.57	-2.58	5.23	-8.58
Capital Expenditures	-0.05	-0.71	-1.16	-0.72	-0.3	-0.03
Free Cash Flow	-3.78	-9.18	-15.73	-3.3	4.93	-8.61
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	45.61%	34.29%	49.33%	41.13%	58.71%	98.29%
Operating Margin	-71.13%	-139.25%	-103.70%	-64.81%	29.65%	-164.85%
Pretax Margin	-66.33%	-138.01%	-158.81%	-61.18%	31.07%	-161.16%
Profit Margin	75.11%	-138.14%	-159.69%	-48.79%	23.66%	-159.09%
FCF Margin	-43.28%	-122.42%	-164.07%	-46.26%	33.80%	-163.71%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 5, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	0.94	-	-	-	4.47	-
Forward PE	-	0.64	0.64	0.64	0.64	0.64
P/FCF Ratio	-	-	-	-	3.13	-
PS Ratio	0.70	0.88	0.50	1.32	1.06	8.30